Biotechnology Science Park Regulation Law In Russia.
1. Introduction
Biotechnology Science Park Regulation Law in Russia concerns the legal framework governing the establishment, registration, financing, operation, supervision and commercial development of biotechnology research parks and innovation centres.
A biotechnology science park is an organised research and commercial environment in which universities, scientific institutions, biotechnology companies, pharmaceutical manufacturers, laboratories, investors and technology-transfer organisations cooperate to develop and commercialise scientific discoveries.
In Russia, biotechnology science parks operate within a broader framework of innovation, industrial development, scientific research, pharmaceutical regulation, intellectual property, environmental protection and special economic zones.
An important legal distinction: Russia does not have one comprehensive federal statute exclusively regulating biotechnology science parks. Their regulation is distributed across several federal laws and special innovation regimes.
The main objectives of this regulatory framework are:
Promoting biotechnology research and innovation.
Encouraging public-private scientific partnerships.
Protecting intellectual property arising from research.
Regulating laboratory and biological safety.
Facilitating commercialisation of biotechnology inventions.
Ensuring pharmaceutical and medical-product compliance.
Preventing environmental and biological risks.
Establishing accountability for science park operators and participating companies.
2. Major legislative framework
The principal legislation includes the following:
| Legislation | Regulatory significance |
|---|---|
| Federal Law No. 244-FZ of 2010 | Skolkovo Innovation Centre |
| Federal Law No. 216-FZ of 2017 | Innovative Scientific and Technological Centres |
| Federal Law No. 116-FZ of 2005 | Special Economic Zones |
| Federal Law No. 488-FZ of 2014 | Industrial parks and technoparks |
| Federal Law No. 127-FZ of 1996 | Science and State Scientific and Technical Policy |
| Federal Law No. 61-FZ of 2010 | Circulation of Medicines |
| Federal Law No. 86-FZ of 1996 | Medicinal Products |
| Federal Law No. 52-FZ of 1998 | Sanitary and Epidemiological Welfare |
| Federal Law No. 7-FZ of 2002 | Environmental Protection |
| Federal Law No. 149-FZ of 2006 | Information and Information Technologies |
| Part IV of the Civil Code | Intellectual property rights |
The precise applicable provisions depend on the legal status of the park, the activities of its residents and the nature of the biotechnology being developed.
2.1 Federal Law No. 244-FZ: Skolkovo Innovation Centre
The Skolkovo Innovation Centre is an important model for understanding Russia's innovation-centre regulatory structure.
Federal Law No. 244-FZ establishes a special legal framework for the creation and functioning of the centre.
Its principal purposes include:
Supporting scientific research and technological development.
Commercialising research results.
Encouraging cooperation between research organisations and businesses.
Providing infrastructure for innovative enterprises.
Establishing a management structure for the innovation centre.
Biotechnology companies can participate in this ecosystem where their projects satisfy the applicable innovation and participation requirements.
For example, a company developing gene-analysis technology, biological diagnostics, pharmaceutical research tools or biotechnology software may seek participation under the relevant innovation-centre arrangements.
Legal significance: The law creates an institutional framework for innovation. It does not automatically exempt biotechnology laboratories from pharmaceutical, sanitary, environmental or biosafety legislation.
CIS Legislation+1
2.2 Federal Law No. 216-FZ of 2017: Innovative Scientific and Technological Centres
Federal Law No. 216-FZ regulates the establishment and operation of Innovative Scientific and Technological Centres (ISTCs).
This legislation is particularly relevant to biotechnology science parks because it supports the development of research infrastructure and commercial applications of scientific discoveries.
Its objectives include:
Increasing investment in scientific research.
Encouraging private-sector participation.
Developing research laboratories and technology infrastructure.
Promoting cooperation between universities and enterprises.
Facilitating the commercial exploitation of scientific results.
A biotechnology centre operating under this framework may provide laboratory facilities, research equipment, incubation services and technology-transfer assistance.
Example: A university and a pharmaceutical research company establish a biotechnology research centre to develop recombinant proteins. The centre must comply with the applicable institutional requirements under Law No. 216-FZ and the separate laws governing the research and production activities.
CIS Legislation
2.3 Federal Law No. 116-FZ of 2005: Special Economic Zones
Federal Law No. 116-FZ provides the legal framework for Special Economic Zones (SEZs).
Technological and innovation-oriented zones can support biotechnology activities through specialised infrastructure and investment incentives.
The relevant regulatory matters include:
Establishment of special economic zones.
Management of zone infrastructure.
Agreements with residents.
Permitted economic activities.
Investment obligations.
Monitoring of compliance.
Termination of resident status where statutory conditions are violated.
A biotechnology enterprise seeking SEZ benefits must satisfy the relevant requirements. Simply locating a laboratory inside an industrial or scientific park does not automatically confer SEZ privileges.
World Trade Organization
2.4 Federal Law No. 488-FZ of 2014: Industrial Technoparks
Federal Law No. 488-FZ on Industrial Policy in the Russian Federation is relevant to the infrastructure and management of industrial technoparks.
Article 19.1 addresses industrial technoparks and the conditions under which industrial-policy support measures may be applied to qualifying management companies and industrial enterprises.
For biotechnology parks, this framework becomes relevant where research is connected with industrial-scale production, such as:
Vaccine manufacturing.
Pharmaceutical ingredients.
Biopharmaceutical production.
Diagnostic reagents.
Industrial enzymes.
Biological materials.
The management company must satisfy applicable government requirements to qualify for the relevant support measures.
Consultant Plus+1
3. Establishment and registration of biotechnology science parks
Establishing a biotechnology science park requires more than registering a company.
The promoters must identify the legal structure under which the park will operate.
Possible structures include:
A. Independent legal entity: A company or non-profit organisation operates research infrastructure and provides services to biotechnology businesses.
B. Innovation-centre structure: The park operates under an applicable innovative scientific and technological centre regime.
C. Special Economic Zone structure: The biotechnology enterprise or infrastructure operates within a designated SEZ.
D. Industrial technopark: The facility supports industrial biotechnology, manufacturing and related technological activities.
The relevant registration and approval requirements depend on the selected structure.
Important establishment requirements
Registration of the operating legal entity.
Lawful rights to land and buildings.
Compliance with planning and construction requirements.
Appropriate laboratory infrastructure.
Fire and occupational safety arrangements.
Sanitary and epidemiological compliance.
Environmental approvals where required.
Equipment certification and calibration where applicable.
Appropriate permissions for regulated biological activities.
Contracts governing access to shared research facilities.
A science park operator must also establish clear contractual relationships with resident companies, research institutions and external service providers.
4. Biotechnology laboratory licensing and biosafety
This is one of the most important regulatory areas for biotechnology science parks.
A science park may contain laboratories conducting recombinant DNA research, microbial engineering, vaccine development, genetic testing and biological-material processing.
The operator and individual research companies must comply with the legislation applicable to their particular activities.
4.1 Federal Law No. 86-FZ of 1996: Genetic Engineering Activities
Federal Law No. 86-FZ regulates genetic-engineering activities, including environmental protection, ecological safety, human-health protection and the legal framework for transferring human genetic data.
Its provisions are relevant to:
Genetically engineered microorganisms.
Recombinant DNA research.
Genetically modified organisms.
Genetic-engineering laboratory operations.
Biological risk assessment.
Environmental release of genetically modified organisms.
Article 7 establishes the genetic-engineering safety framework, including risk assessment and state monitoring.
Article 8 addresses the professional and organisational requirements for persons and legal entities undertaking genetic-engineering activities.
Article 12 provides for responsibility where genetic-engineering activities cause harm or violate applicable legal requirements.
A particularly important distinction is between contained laboratory research and activities involving the release of genetically modified organisms into the environment.
The amended law must be consulted in its current form: Federal Law No. 43-FZ of 20 February 2026 introduced further amendments effective from 1 September 2026.
CIS Legislation+3
4.2 Federal Law No. 492-FZ of 2020: Biological Safety
Federal Law No. 492-FZ on Biological Safety in the Russian Federation provides a broader framework for protecting people and the environment against dangerous biological factors.
It is relevant to science parks containing:
Pathogen research laboratories.
Microbiological research facilities.
Vaccine-development laboratories.
Biological-material storage facilities.
Genetic-engineering research units.
Laboratories working with potentially dangerous biological agents.
The legislation addresses biological threats, biological risks and state measures for monitoring and preventing biological hazards.
Example: If a biotechnology laboratory experiences an accidental release of a dangerous biological agent, the incident may engage the responsibilities of the laboratory operator, responsible personnel and relevant supervisory authorities.
CIS Legislation
4.3 Licensing of specialised biological activities
Certain activities involving infectious disease pathogens and specified genetically modified organisms require licensing under the applicable Russian licensing framework.
Relevant requirements may include:
Suitable laboratory premises.
Qualified personnel.
Appropriate equipment.
Secure biological-material storage.
Documented safety procedures.
Risk-management systems.
Compliance with government licensing conditions.
A science park's general registration does not replace an individual laboratory's required licence.
4.4 Sanitary and epidemiological supervision
Federal Law No. 52-FZ of 1999, concerning the sanitary and epidemiological welfare of the population, is another important part of the framework.
It affects:
Laboratory hygiene.
Biological exposure prevention.
Workplace sanitary conditions.
Waste-handling procedures.
Protection of employees and surrounding communities.
Sanitary supervision of relevant premises and activities.
The regulatory obligations depend on the laboratory's activities and the applicable sanitary rules.
5. Pharmaceutical and medical biotechnology regulation
Biotechnology science parks frequently support pharmaceutical and medical research.
However, developing a medicine inside a science park does not automatically authorise its manufacture, clinical investigation or commercial distribution.
5.1 Federal Law No. 61-FZ of 2010: Circulation of Medicines
This law governs the circulation of medicinal products in Russia.
Its regulatory scope includes:
Pharmaceutical development.
Clinical investigations.
Registration of medicinal products.
Manufacturing.
Quality control.
Storage.
Distribution.
Pharmacovigilance.
A biotechnology company developing monoclonal antibodies, recombinant proteins, vaccines or biological medicines must satisfy the applicable pharmaceutical requirements.
5.2 Clinical research
Clinical investigations involving biotechnology-based medicines must follow the applicable legal and ethical requirements.
Relevant considerations include:
Scientific justification.
Appropriate clinical-investigation authorisation.
Ethics review.
Informed consent.
Patient protection.
Research documentation.
Adverse-event reporting.
Data integrity.
The science park operator should ensure that shared infrastructure contracts clearly allocate responsibilities between the operator, sponsor, investigator and research institution.
5.3 Good Manufacturing Practice
Biopharmaceutical manufacturing must satisfy applicable Good Manufacturing Practice requirements.
For Russian manufacturers, the Eurasian Economic Union pharmaceutical regulatory framework is also important.
The relevant standards address:
Manufacturing quality systems.
Personnel qualifications.
Cleanroom conditions.
Contamination prevention.
Batch documentation.
Quality assurance.
Product traceability.
6. Intellectual property rights in biotechnology science parks
Intellectual property is a central legal issue because science parks encourage collaboration between universities, private enterprises and research organisations.
Part IV of the Russian Civil Code governs intellectual property rights.
Relevant forms of protection include:
| Intellectual property | Biotechnology application |
|---|---|
| Patents | Biotechnology inventions and technical processes |
| Copyright | Research software and scientific publications |
| Trade secrets | Confidential laboratory methods |
| Know-how | Proprietary production techniques |
| Trademarks | Pharmaceutical and biotechnology brands |
| Database rights | Protected research databases |
6.1 Ownership of scientific inventions
A major problem arises when university researchers, science park employees and private companies jointly develop a biotechnology invention.
The parties must determine:
Who owns the invention?
Who is entitled to file a patent application?
Who owns improvements?
Whether the university retains rights.
Whether the company receives an exclusive licence.
How commercial revenues are distributed.
Russian patent law recognises the distinction between employee inventions and inventions developed under contractual arrangements.
6.2 Research collaboration agreements
A biotechnology science park should encourage written research collaboration agreements.
Such agreements should cover:
Background intellectual property.
Ownership of newly developed inventions.
Patent application responsibilities.
Confidentiality.
Publication rights.
Research-material transfers.
Licensing and royalty payments.
Dispute resolution.
Example: A Russian university provides researchers and laboratory facilities, while a pharmaceutical company finances the development of a new vaccine platform. The agreement should specify ownership and licensing rights before research begins.
7. Environmental protection and waste management
Biotechnology parks can generate biological, chemical and pharmaceutical waste.
Their operations must therefore comply with the applicable environmental and waste-management legislation.
Important legislation includes:
Federal Law No. 7-FZ of 2002 on Environmental Protection.
Federal Law No. 89-FZ of 1998 on Production and Consumption Waste.
Federal Law No. 52-FZ of 1999 on Sanitary and Epidemiological Welfare.
Principal regulatory obligations include:
A. Biological waste management: Proper handling, treatment and disposal of biological waste.
B. Chemical waste management: Safe disposal of laboratory chemicals and hazardous substances.
C. Wastewater management: Prevention of contamination of water systems.
D. Air-pollution control: Compliance with applicable emissions standards.
E. Environmental assessment: Obtaining environmental assessments and approvals where legally required.
F. Emergency management: Procedures for spills, contamination and accidental releases.
Where a laboratory causes environmental damage, the responsible organisation may face administrative, civil or criminal consequences depending on the circumstances.
8. Governance and regulatory supervision
Biotechnology science parks involve multiple institutional actors.
| Institution | Principal responsibility |
|---|---|
| Ministry of Science and Higher Education | Scientific and research policy |
| Ministry of Industry and Trade | Industrial and pharmaceutical policy |
| Ministry of Health | Healthcare and pharmaceutical regulation |
| Rospotrebnadzor | Sanitary and epidemiological supervision |
| Rosprirodnadzor | Environmental supervision |
| Rospatent | Intellectual property registration |
| Federal Tax Service | Tax compliance and relevant tax incentives |
| Relevant regional authorities | Regional infrastructure and development |
The precise authority depends on the activity being regulated.
8.1 Responsibilities of the park management company
The management company is responsible for managing the park in accordance with its legal structure and applicable agreements.
Its functions may include:
Managing laboratory infrastructure.
Providing common research facilities.
Allocating research space.
Managing access to technical equipment.
Supervising contractual compliance.
Coordinating infrastructure maintenance.
Managing safety and emergency procedures.
Supporting technology transfer.
However, the management company does not automatically assume all statutory responsibilities of individual resident companies.
For example, a pharmaceutical resident remains responsible for obtaining the product approvals and manufacturing permissions required for its own operations.
9. Tax incentives and financial regulation
Russia provides specialised tax arrangements for qualifying innovation-centre participants and special economic zone residents.
However, tax incentives are conditional and should not be treated as automatic benefits for every company operating inside a biotechnology park.
Under the relevant Skolkovo framework, eligible participants may obtain tax benefits under the Tax Code, subject to applicable statutory conditions.
Important considerations include:
Valid participant status.
Eligible research activities.
Compliance with reporting obligations.
Appropriate financial records.
Compliance with revenue and other statutory thresholds.
Correct treatment of research grants and commercial income.
The distinction between ordinary park tenants and formally recognised innovation-centre participants is particularly important.
WIPO Lex+2
10. Important case laws and judicial principles
An important research limitation must be recognised: there is no readily identifiable, established body of published Russian court judgments specifically addressing the regulation of biotechnology science parks as a distinct legal subject.
Russian disputes are more commonly resolved under general rules concerning tax benefits, contractual obligations, intellectual property, licensing, environmental liability and administrative supervision.
The following judicial authorities and principles are relevant to analysing such disputes.
Case 1. Resolution of the Plenum of the Supreme Arbitration Court No. 53 of 12 October 2006
Subject: Assessment of the grounds for obtaining tax benefits.
This resolution provides important judicial guidance concerning claims for unjustified tax benefits.
The court guidance requires attention to the economic substance of transactions and whether the taxpayer's claimed activities are genuine.
Relevance to biotechnology science parks:
A biotechnology company claiming innovation-related tax benefits must maintain credible evidence of its research activities, financial transactions, personnel, equipment and commercial operations.
A company cannot safely rely on its formal association with an innovation centre if the underlying statutory conditions are not satisfied.
english.garant.ru
Case 2. Skolkovo Innovation Centre participant-status disputes
Subject: Eligibility for innovation-centre participation and associated privileges.
Federal Law No. 244-FZ establishes statutory conditions for obtaining and retaining project-participant status.
Article 10 addresses inclusion in the register and circumstances in which participant status may be terminated.
The relevant legal principles include:
Compliance with participation requirements.
Genuine research and development activities.
Observance of project rules.
Proper maintenance of participant records.
Compliance with applicable reporting requirements.
Biotechnology relevance: A company conducting pharmaceutical or genetic-engineering research must establish that its activities fall within the relevant approved research framework and comply with the applicable participant conditions.
This is a statutory application rather than a claim that a particular biotechnology judgment has established the principle.
WIPO Lex+1
Case 3. Russian GMO regulatory enforcement disputes
Subject: Compliance with genetic-engineering requirements.
Federal Law No. 86-FZ establishes the statutory basis for regulating genetic-engineering activities.
Article 7 addresses safety and monitoring, while Article 12 establishes responsibility for relevant violations.
These provisions provide the legal basis for disputes involving:
Unauthorised genetic-engineering activities.
Non-compliant use of genetically modified organisms.
Environmental contamination.
Failure to comply with safety requirements.
Damage to human health or the environment.
Biotechnology relevance: A science park laboratory conducting genetic-engineering experiments must comply with the applicable requirements regardless of whether it is located in an innovation centre.
ТКС.РУ+1
Case 4. Special Economic Zone resident-status disputes
Subject: Compliance with resident agreements and investment obligations.
Federal Law No. 116-FZ establishes the legal framework for SEZ residents.
Its provisions concerning technological and innovative activities include consequences for termination of the relevant agreement and loss of resident status.
Biotechnology relevance: A biotechnology company operating in an SEZ may face disputes concerning:
Failure to meet investment commitments.
Failure to undertake approved activities.
Breach of resident agreements.
Loss of special economic status.
Tax treatment following termination.
These are relevant statutory dispute categories, not individually identified biotechnology judgments.
World Trade Organization+1
Case 5. Intellectual property disputes involving research organisations
Subject: Ownership and commercialisation of research inventions.
Russian Civil Code Part IV provides the principal legal framework for disputes involving patents, employee inventions, licences and know-how.
Potential disputes include:
University versus researcher ownership claims.
Disagreements between research institutions and pharmaceutical companies.
Unauthorised commercialisation of patented inventions.
Breach of technology-transfer agreements.
Misappropriation of confidential laboratory information.
Biotechnology relevance: These principles become particularly important when a science park operates joint research programmes with universities and commercial enterprises.
Note: These are categories of disputes governed by Russian intellectual property law, not references to a particular identified court judgment.
11. Legal liabilities for biotechnology science parks
Different types of liability may arise depending on the nature of the violation.
| Violation | Potential legal consequence |
|---|---|
| Unlicensed regulated biological activity | Administrative or other applicable liability |
| Breach of biological safety requirements | Regulatory sanctions and possible suspension |
| Environmental contamination | Environmental compensation and other liability |
| Pharmaceutical manufacturing violations | Regulatory action and product restrictions |
| Patent infringement | Injunctions and damages |
| Breach of research contracts | Contractual damages |
| Tax-benefit misuse | Tax reassessment, penalties and interest |
| Occupational safety violations | Administrative, civil or criminal liability |
Russian administrative liability is principally governed by the Code of Administrative Offences.
Civil liability is governed by the Civil Code, while criminal liability may arise where the elements of a relevant Criminal Code offence are established.
12. Practical example: Establishment of a biotechnology science park
Consider a hypothetical Russian biotechnology science park established to support vaccine development and genetic-engineering research.
The park contains:
A university biotechnology laboratory.
A pharmaceutical research company.
A vaccine-development facility.
A genetic-engineering research unit.
A biological-material storage facility.
A technology-transfer office.
The legal responsibilities would be divided as follows:
| Activity | Applicable regulatory framework |
|---|---|
| Establishing the innovation centre | Laws No. 216-FZ or 244-FZ, where applicable |
| Industrial infrastructure | Law No. 488-FZ |
| SEZ participation | Law No. 116-FZ |
| Genetic engineering | Law No. 86-FZ |
| Biological safety | Law No. 492-FZ |
| Pharmaceutical development | Law No. 61-FZ |
| Sanitary protection | Law No. 52-FZ |
| Environmental compliance | Law No. 7-FZ |
| Patent ownership | Civil Code Part IV |
| Tax incentives | Russian Tax Code |
Suppose the vaccine-development company accidentally releases biological material outside its designated laboratory.
The legal consequences may include:
Immediate safety and containment measures.
Notification to competent authorities where required.
Investigation of the incident.
Assessment of environmental and public-health consequences.
Examination of laboratory safety documentation.
Determination of responsibility of the relevant organisations and individuals.
Compensation or sanctions where liability is established.
The science park's innovation status would not protect the company from these obligations.
13. Major regulatory challenges
Russia's biotechnology science park framework faces several important legal and institutional challenges.
1. Fragmented legislation: Innovation-centre regulation, biotechnology safety and pharmaceutical regulation are governed by different legal instruments.
2. Research-to-commercialisation gap: A scientific discovery may be commercially promising but still require separate regulatory approval before entering the pharmaceutical market.
3. Biosafety accountability: Shared laboratories create questions about the allocation of responsibility between park operators and resident companies.
4. Intellectual property ownership: Joint research can produce disagreements over patent ownership, licensing and commercial revenue.
5. Environmental responsibility: Biological and pharmaceutical waste requires appropriate management.
6. Tax compliance: Innovation incentives depend on statutory eligibility rather than merely operating within a science park.
7. International cooperation: Foreign research collaborations may involve additional rules on genetic data, technology transfers, sanctions, export controls and research-material transfers.
14. Suggestions for strengthening Russian biotechnology science park regulation
Several legal and institutional improvements could strengthen the regulatory system:
Develop clearer biotechnology-specific science park accreditation standards.
Introduce consistent laboratory safety auditing requirements.
Establish standard research collaboration agreements.
Improve intellectual property ownership guidelines.
Strengthen biological incident reporting.
Improve coordination between science, health and environmental regulators.
Clarify responsibilities for shared research infrastructure.
Develop transparent procedures for innovation-centre participant status.
Encourage lawful technology transfer and commercialisation.
Strengthen independent compliance and safety assessments.
15. Conclusion
Biotechnology Science Park Regulation Law in Russia is based on a combination of innovation-centre legislation, industrial policy, genetic-engineering regulation, biological safety, pharmaceutical legislation, environmental protection and intellectual property law.
Federal Law No. 244-FZ provides a special framework for the Skolkovo Innovation Centre, while Federal Law No. 216-FZ governs Innovative Scientific and Technological Centres. Federal Laws Nos. 116-FZ and 488-FZ provide additional frameworks for special economic zones and industrial technoparks.
For biotechnology enterprises, the most important legal distinction is between permission to participate in an innovation ecosystem and permission to undertake regulated biological, pharmaceutical or manufacturing activities.
The central legal principle is that innovation incentives do not replace biosafety, pharmaceutical, environmental and intellectual property obligations. A biotechnology science park must therefore combine research freedom with statutory compliance, institutional accountability and protection of public health.
16. Important legislation and research references
For further legal research, the following primary sources are useful:
Federal Law No. 244-FZ – Skolkovo Innovation Centre.
Federal Law No. 216-FZ – Innovative Scientific and Technological Centres.
Federal Law No. 116-FZ – Special Economic Zones.
Federal Law No. 488-FZ – Industrial Technoparks.
Federal Law No. 86-FZ – Genetic Engineering Activities.
Federal Law No. 492-FZ – Biological Safety.
Supreme Arbitration Court Plenum Resolution No. 53 of 2006 – Tax Benefits.
Research note: This is an academic overview of the Russian legal framework as of 18 November 2026, not an exhaustive case-law digest or a substitute for checking the current official Russian-language legislation and individual regulatory approvals.

comments